Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Qureight closes $20 million Series B financing

30

Jul 2026

Qureight closes $20 million Series B financing

Qureight, an end-to-end imaging company that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, today announced it has raised $20 million in a Series B financing, led by Molten Ventures.

Cigarette smoke extract primes airway cells for greater nanoplastic damage

30

Jul 2026

Cigarette smoke extract primes airway cells for greater nanoplastic damage

Researchers found that cigarette smoke extract weakened epithelial barriers and increased the proportion of human airway cells that were polystyrene nanoparticle-positive. Sequential treatment caused greater metabolic disruption and increased mucus-producing cells, suggesting heightened epithelial vulnerability, although the findings are limited to in vitro models.

Combination therapy improves progression-free survival in dMMR/MSI-H metastatic colorectal cancer

29

Jul 2026

Combination therapy improves progression-free survival in dMMR/MSI-H metastatic colorectal cancer

Patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer experienced a 58% reduction in the risk of disease progression or death when treated with atezolizumab plus modified FOLFOX6 and bevacizumab compared with atezolizumab alone, according to results from the NRG-GI004/SWOG S1610 COMMIT trial published recently in the Journal of Clinical Oncology.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.